Biotech Movers: Affymax Crashes on Recall

by Kyle Woodley | March 4, 2013 8:40 am

[1]Here’s a look at recent major developments and share moves[2] in biotech stocks:

Affymax (NASDAQ:AFFY[3]): Affymax announced last week that it and Japanese partner Takeda Pharmaceutical (PINK:TKPYY[4]) were pulling back injectable units of its anemia drug Omontys amid news of severe reactions and even death in some patients — news that sent shares crashing by more than 80%. Omontys is Affymax’s sole commercial drug, and MLV & Co analyst added that AFFY “has no pipeline to speak of”[5] in a report downgrading the stock.

MediciNova (NASDAQ:MNOV[6]): MediciNova shares jumped almost 47% last week after receiving an FDA Fast Track designation for ibudilast, a treatment for methamphetamine dependence. The Fast Track designation[7] is given to drugs that treat serious diseases and fill unmet medical needs, and can speed the process of approval; there currently are no FDA-approved treatments for meth dependence. MNOV has no commercial drugs.

Vivus (NASDAQ:VVUS[8]): Vivus — maker of weight-loss drug Qsymia — fell nearly 18% last week after reporting a much wider fourth-quarter loss than in the year-ago period. VVUS lost $56.7 million in Q4 2012 — about five times its loss in Q4 2011 — thanks to higher expenses, including those related to sales of Qsymia. That helped push a full-year loss of $139.9 million compared to 2011’s $46.1 million loss. However, Vivus did record $2 million in sales, vs. zero in the year-ago quarter.

Anacor Pharmaceuticals (NASDAQ:ANAC[9]): Anacor climbed 20% last week after announcing promising results from a Phase 3 trial[10] for tavaborole, a topical treatment for the fungal infection onychomycosis. In a release, CEO David Perry said, “In both Phase 3 trials, tavaborole demonstrated better efficacy than ciclopirox lacquer, the only approved topical treatment for onychomycosis.” In the study, 27.5% of patients achieved a completely clear or almost clear nail, while the drug completely cured the condition in 9.1% of the patients.

Sangamo Biosciences (NASDAQ:SGMO[11]): Sangamo — a biopharma company involved in using engineered DNA-binding proteins to treat several diseases — gained about 15% last week after a Lazard Capital Markets analyst initiated coverage on SGMO[12] with a “buy” recommendation and a $16 target price — roughly 85% higher than last Monday’s closing price. SGMO currently has an HIV/AIDS treatment, SB-728, in Phase 2 trials.

Kyle Woodley[13] is the Deputy Managing Editor of[14]. As of this writing, he did not hold a position in any of the aforementioned securities. Follow him on Twitter at @IPKyleWoodley[15].

  1. [Image]:
  2. recent major developments and share moves:
  3. AFFY:
  4. TKPYY:
  5. “has no pipeline to speak of”:
  6. MNOV:
  7. Fast Track designation:
  8. VVUS:
  9. ANAC:
  10. promising results from a Phase 3 trial:
  11. SGMO:
  12. initiated coverage on SGMO:
  13. Kyle Woodley:
  15. @IPKyleWoodley:

Source URL:
Short URL: